BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19823672)

  • 1. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance.
    Duan Z; Choy E; Hornicek FJ
    PLoS One; 2009 Oct; 4(10):e7415. PubMed ID: 19823672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.
    Yang X; Yang P; Shen J; Osaka E; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
    Br J Cancer; 2014 Jun; 110(12):2896-904. PubMed ID: 24853187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
    Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
    Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay.
    Susa M; Choy E; Yang C; Schwab J; Mankin H; Hornicek F; Duan Z
    J Biomol Screen; 2010 Mar; 15(3):287-96. PubMed ID: 20150589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.
    Ye S; Zhang J; Shen J; Gao Y; Li Y; Choy E; Cote G; Harmon D; Mankin H; Gray NS; Hornicek FJ; Duan Z
    Br J Pharmacol; 2016 Feb; 173(3):613-26. PubMed ID: 26603906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
    Yang X; Shen J; Gao Y; Feng Y; Guan Y; Zhang Z; Mankin H; Hornicek FJ; Duan Z
    Int J Cancer; 2015 Oct; 137(8):2029-39. PubMed ID: 25904021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer.
    Duan Z; Li X; Huang H; Yuan W; Zheng SL; Liu X; Zhang Z; Choy E; Harmon D; Mankin H; Hornicek F
    J Med Chem; 2012 Apr; 55(7):3113-21. PubMed ID: 22400811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
    Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
    Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells.
    Zhang DM; Li YJ; Shu C; Ruan ZX; Chen WM; Yiu A; Peng YH; Wang J; Lan P; Yao Z; Fung KP; Fu LW; Chen ZS; Ye WC
    Anticancer Drugs; 2013 Jun; 24(5):441-54. PubMed ID: 23466650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
    Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
    Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP.
    Germann UA; Ford PJ; Shlyakhter D; Mason VS; Harding MW
    Anticancer Drugs; 1997 Feb; 8(2):141-55. PubMed ID: 9073310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein.
    Mi Y; Lou L
    Br J Cancer; 2007 Oct; 97(7):934-40. PubMed ID: 17912240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance.
    Zahra R; Furqan M; Ullah R; Mithani A; Saleem RSZ; Faisal A
    PLoS One; 2020; 15(6):e0233993. PubMed ID: 32484843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.
    Li J; Xu LZ; He KL; Guo WJ; Zheng YH; Xia P; Chen Y
    Breast Cancer Res; 2001; 3(4):253-63. PubMed ID: 11434876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.
    Duan Z; Zhang J; Ye S; Shen J; Choy E; Cote G; Harmon D; Mankin H; Hua Y; Zhang Y; Gray NS; Hornicek FJ
    BMC Cancer; 2014 Sep; 14():681. PubMed ID: 25236161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro.
    Germann UA; Shlyakhter D; Mason VS; Zelle RE; Duffy JP; Galullo V; Armistead DM; Saunders JO; Boger J; Harding MW
    Anticancer Drugs; 1997 Feb; 8(2):125-40. PubMed ID: 9073309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
    Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
    Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
    Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.